Ki-Ho Kim
Directeur Général chez SAMSUNG PHARM. CO., LTD.
Fortune : 878 404 $ au 30/04/2024
Provenance du réseau au premier degré de Ki-Ho Kim
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Industrial Machinery | 7 | |
| Public Company | Pharmaceuticals: Major | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Ki-Ho Kim via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| FLASK CO., LTD. | Electronic Production Equipment | Director/Board Member Director/Board Member | |
| GEMVAXLINK CO., LTD. | Apparel/Footwear Retail | Chief Executive Officer Director/Board Member | |
| KB INSURANCE CO LTD | Multi-Line Insurance | President | |
| DREAMCIS, INC. | Miscellaneous Commercial Services | Chief Executive Officer | |
| Korea University | College/University | Graduate Degree | |
| Teloid, Inc. | Chief Executive Officer | ||
NovaHep AB
 NovaHep AB Miscellaneous Commercial ServicesCommercial Services NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
Gemvax AS
 Gemvax AS Pharmaceuticals: MajorHealth Technology Part of GemVax & KAEL Co., Ltd., Gemvax AS is a Norwegian peptide-based drug development company that focuses on researching and developing treatments for Alzheimer's disease and prostate hyperplasia. The company is based in Porsgrunn, Norway. The company also develops and sell products such as CA filters and provide investment information. The company was founded by Mona Elisabeth Møller. Gemvax was acquired by VaxOnco, Inc. from Pharmexa A/S on October 30, 2008. | Pharmaceuticals: Major | Director/Board Member | |
| Gemvax USA, Inc. | Chief Executive Officer | ||
| Seoul National University | College/University | Graduate Degree | |
Gem & Co. /KR/
 Gem & Co. /KR/ Investment ManagersFinance Gem & Co. /KR/ engages in the provision of financial consulting and trading services. The company was founded on September 9, 2004 and is headquartered in Seongnam, South Korea. | Investment Managers | Chief Executive Officer | |
| Hanyang University | College/University | Doctorate Degree | |
Korea Stem Cell Bank Co., Ltd.
 Korea Stem Cell Bank Co., Ltd. BiotechnologyHealth Technology Korea Stem Cell Bank Co., Ltd. develops stem cell storage and treatment technology solutions. It also engages in the research and development of stem cell therapies to treat various diseases, including cancers, chronic, and incurable diseases. The company was founded on December 20, 2005 and is headquartered in Seongnam-si, South Korea. | Biotechnology | Chief Executive Officer | |
KAEL-GemVax Co., Ltd.
 KAEL-GemVax Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of GemVax & KAEL Co., Ltd., KAEL-GemVax Co., Ltd. manufactures bio-pharmaceutical products. The company is based in Seongnam, South Korea. The CEOs of the South Korean company are Gyeong Hee Kim, Sang-Jae Kim, Magnus Moliteus. | Pharmaceuticals: Major | Chief Executive Officer | |
| Yonsei University | College/University | Graduate Degree |
Statistiques
Internationale
| Corée du Sud | 14 |
| Etats-Unis | 3 |
| Suède | 2 |
| Norvège | 2 |
Sectorielle
| Consumer Services | 5 |
| Health Technology | 4 |
| Electronic Technology | 3 |
| Finance | 3 |
| Commercial Services | 3 |
Opérationnelle
| Director/Board Member | 19 |
| Chief Executive Officer | 11 |
| Graduate Degree | 4 |
| President | 2 |
| Independent Dir/Board Member | 2 |
Relations les plus connectées
| Insiders | |
|---|---|
| Sang-Jae Kim | 14 |
| Gi-Woong Kim | 6 |
| Woo-Jin Kim | 3 |
| Kyung-Sun Gong | 3 |
| Chang-Ro Lee | 1 |
| Chang-Bum Woo | 1 |
| Se-Yeol Lee | 1 |
| Sung-Yeol Kim | 1 |
